← All trials
NCT02366884
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2011
- Primary completion
- Dec 1, 2017
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Dr. Frank Arguello Cancer ClinicLead sponsor
- Dr. Frank Arguello Cancer ClinicOverall official - principal investigator
- Instituto de Ciencia y Medicina GenomicaOverall official - principal investigator
- Dr. Frank Arguello Cancer ClinicReponsible party - principal investigator
- Instituto de Ciencia y Medicina GenomicaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.